FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to psychiatry and neurology, and can be used to assess the severity of anti-N-methyl-D-aspartate (NMDA) receptor encephalitis with manifested psychopathological symptoms. Patient’s blood is sampled to detect autoantibodies to the NR1 NMDA receptor subunit. Antibodies to neurospecific glial fibrillar acidic protein (GFAP) and neuron-specific enolase (NSE) are determined in patient's blood serum. If the NR1 antibody test is positive, antibody titre to GFAP is 1:100 and higher, and antibody titre to NSE is 1:100 and higher, the patient’s condition is considered to be severe.
EFFECT: method provides the possibility of increasing the accuracy of assessing the severity of anti-NMDA-receptor encephalitis in patients with a predominance of psychopathological symptoms by detecting in the patients a complex of antibodies to NMDA-receptors, GFAP and NSE in blood serum, where antigens used are recombinant proteins: 2 extracellular domains of subunit of NR1 NMDA receptor – Ed1 and Ed2, GFAP and NSE.
1 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF COMORBID COURSE OF AFFECTIVE DISORDERS AND ALCOHOLISM BASED ON DETERMINATION OF BLOOD SERUM PROTEINS | 2021 |
|
RU2767699C1 |
| BIOMARKERS OF ISCHEMIA AND THEIR APPLICATION FOR PREDICTION OF UNFAVOURABLE NEUROLOGIC CONSEQUENCES OF SURGICAL OPERATION | 2006 |
|
RU2435165C2 |
| METHOD FOR PREDICTING THE CLINICAL COURSE OF AFFECTIVE DISORDER IN BIPOLAR AND MONOPOLAR DEPRESSIVE TYPE BASED ON DETERMINATION OF BLOOD SERUM PROTEINS | 2024 |
|
RU2835348C1 |
| METHOD OF ASSESSING THE RISK OF AGGRESSIVE BEHAVIOR IN PERSONS WITH SEVERE MENTAL DISORDERS | 2023 |
|
RU2804673C1 |
| METHOD FOR DETERMINING COMPLEMENT-ACTIVATING FUNCTION OF SARS-CoV-2 ANTIBODIES FOR PREDICTING SEVERITY OF COVID-19 | 2023 |
|
RU2818351C1 |
| METHOD OF PREDICTING SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE IN HUMAN BODY IN DISEASES | 2022 |
|
RU2808416C1 |
| EARLY DIAGNOSTIC TECHNIQUE FOR CLINICAL COURSE AND OUTCOME OF NEUROTIC, STRESS-RELATED CONNECTED WITH STRESS, SOMATOFORM AND NEUROSIS-LIKE DISORDERS | 2009 |
|
RU2427841C2 |
| METHOD FOR DETECTING ANTIBODIES IN BLOOD SERUM ASSOCIATED WITH AUTOIMMUNE ENDOCRINE AND COMORBID PATHOLOGIES ON HYDROGEL BIOCHIP | 2022 |
|
RU2816512C1 |
| METHOD OF LOW-INTENSIVE LASER THERAPY OF NEUROTIC DISORDERS | 2009 |
|
RU2440161C2 |
| METHOD FOR PREDICTION OF RISK OF FORMATION OF ORGANIC ANXIETY DISORDER | 2019 |
|
RU2712915C1 |
